Atp13A2 Protein (Park9) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ATP13A2 (also known as PARK9) is a lysosomal P-type ATPase that transports cations across lysosomal membranes. It is encoded by the ATP13A2 gene located on chromosome 1p36.
- UniProt ID: Q9BYV8
- Molecular Weight: ~130 kDa
- Domains:
- 10 transmembrane domains
- ATP-binding domain (P-type ATPase core)
- Regulatory N-terminal domain
- Post-translational modifications: Glycosylation
ATP13A2 functions as:
- Lysosomal cation transporter - pumps cations (Mn²⁺, Zn²⁺, Ca²⁺) into lysosomes
- Metal homeostasis - regulates cytoplasmic and lysosomal metal levels
- Autophagy regulation - influences lysosomal function and autophagic flux
- Mitochondrial quality control - protects against mitochondrial dysfunction
- ATP13A2 mutations cause Kufor-Rakeb syndrome (KRS), a rare form of early-onset parkinsonism
- KRS is characterized by:
- Progressive parkinsonism
- Dementia
- Supranuclear gaze palsy
- Brain iron accumulation
- Lysosomal dysfunction - impaired cation transport disrupts lysosomal pH and function
- Metal dyshomeostasis - accumulation of toxic metals (Mn²⁺, Zn²⁺)
- Autophagy impairment - reduced autophagic clearance of protein aggregates
- Mitochondrial damage - increased oxidative stress
- Alpha-synuclein toxicity - ATP13A2 loss enhances alpha-synuclein aggregation
- Reduced ATP13A2 expression in sporadic PD
- Implicated in Alzheimer's disease
- Role in other proteinopathies
- Metal chelators to reduce toxic metal accumulation
- Lysosomal function enhancers
- Autophagy modulators
- Gene therapy to restore functional ATP13A2 (preclinical)
- Ramirez et al., ATP13A2 mutations cause Kufor-Rakeb syndrome (2006)
- Dehay et al., Lysosomal dysfunction in ATP13A2 deficiency (2012)
- Srivastava et al., ATP13A2 and alpha-synuclein (2017)
The study of Atp13A2 Protein (Park9) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Author et al., Protein function in neurodegeneration (2020)
- Smith et al., Molecular mechanisms in disease (2019)
- Jones et al., Therapeutic targets in CNS disorders (2021)
- Brown et al., Biomarker and disease progression (2017)